Date: 2011-02-09
Type of information: Development agreement
Compound: antibody-based therapeutics
Company: Boehringer Ingelheim (Germany) Elan (Ireland)
Therapeutic area: undisclosed
Type agreement: Development
Manufacturing
Production
Action mechanism:
Disease: undisclosed
Details: Elan and Boehringer Ingelheim have entered into a global technical development and manufacturing agreement for antibody-based therapeutics. Under the terms of the agreement, Boehringer Ingelheim will perform the technical development, clinical manufacturing and related regulatory filing support services for antibodies discovered by Elan. Elan will lead the discovery science, preclinical activities, clinical development and commercialization of such antibodies.
Financial terms:
Latest news:
